Posted on Tuesday, 22nd December 2009 by admin

Pharmaceutical companies are being forced to cut the price of high cost cancer drugs for the first time as a result of a tough new approach by the NHS medicines watchdog, the National Institute for Clinical Excellence (Nice). In the latest example, Nice has today announced approval of trabectedin, a drug for soft tissue sarcoma, [...]

Tags: , , , , ,
Posted in News | Comments (0)